Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968952 | 0.81 | HDAC4 (0.60) | SIRT2SIRT1TGM2SIRT5SIRT3 | |
| SCHEMBL963549 | 0.79 | MGLL (0.50) | TGM2MGLL | |
| SCHEMBL22034400 | 0.78 | SIRT5 (0.57) | SIRT2SIRT1SIRT5SIRT3MGLL | |
| SCHEMBL22034402 | 0.78 | SIRT5 (0.57) | SIRT2SIRT1SIRT5SIRT3MGLL | |
| SCHEMBL3460295 | 0.78 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL13227705 | 0.78 | FOLH1 (0.69) | SIRT2SIRT1TGM2 | |
| SCHEMBL31265517 | 0.78 | FOLH1 (0.69) | SIRT2SIRT1TGM2 | |
| SCHEMBL31265519 | 0.78 | FOLH1 (0.69) | SIRT2SIRT1TGM2 | |
| SCHEMBL19688778 | 0.78 | MGLL (0.76) | MGLL | |
| SCHEMBL17133762 | 0.77 | TGM2 (0.57) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | SIRT2 1457/4885SIRT1 1060/4885TGM2 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.